Selecta Biosciences (SELB) – Company Press Releases
-
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
-
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
-
Selecta Biosciences Announces Merger with Cartesian Therapeutics
-
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
-
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
-
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
-
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
-
Cellarity Strengthens Executive Leadership Team
-
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
-
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
-
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
-
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
-
Selecta Biosciences Provides Business Update and Outlook for 2023
-
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
-
Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
-
Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer
-
Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day
-
Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
-
Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
-
Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions
-
Selecta Biosciences to Participate in Upcoming Investor Conferences
-
Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
-
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Selecta Biosciences to Participate in Upcoming Investor Conferences
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update
-
Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
-
Surface Oncology Appoints Carsten Brunn to Board of Directors
-
Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates
-
Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
-
Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
-
Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
-
Selecta Biosciences Announces $38.7 Million Underwritten Offering
-
Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference
-
Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Provide Business Update
-
Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
-
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
-
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
-
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
-
Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event
-
Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout
-
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
-
Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia
-
Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference
-
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy
Back to SELB Stock Lookup